Help us determine the safety and efficacy of an ALS drug

Study ended

Study Name
Orphazyme-Arimoclomol Phase III Clinical Trial
Michael Benatar, MD, PhD
Study Type
Interventional (Clinical Trial), Phase 3, Randomized, Double-Blind, Placebo-controlled
Eligible Population

Individuals affected with ALS, with symptoms of weakness appearing less than 18 months prior to enrollment and preserved respiratory function

Study Purpose/Goals

To evaluate the efficacy and safety of arimoclomol in ALS.

A Phase 3, Randomized, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis


82 weeks (~1.5 years) of participation

  • Medical history and medication review
  • Drug dosing with diary tracking
  • Breathing testing
  • Neuropsychological testing
  • Questionnaires/Surveys
  • Physical exam
  • Neurological exam
  • Electrocardiogram
  • Blood, urine, and CSF collection

Join our family - together, we can change the course of this disease.

Join our family

Together, we can change the course of this disease.

Copyright © 2020. ALS Center at the University of Miami. All Rights Reserved. Branding by Mok2